HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
methanol extraction residue (MER) tubercle bacillus fraction
extract of phenol killed, acetone washed tubercle bacilli (BCG attenuated)
Also Known As:
MER (methanol-extraction residue), tubercle bacillus fraction; MER-BCG; NSC-143769
Networked:
17
relevant articles (
0
outcomes,
4
trials/studies)
Bio-Agent Context: Research Results
Complex Mixtures: 1906
Biological Products
Vaccines: 124365
Bacterial Vaccines: 529
Tuberculosis Vaccines: 243
BCG Vaccine: 1485
methanol extraction residue (MER) tubercle bacillus fraction: 17
Related Diseases
1.
Neoplasms (Cancer)
01/01/1987 - "
Novel approach to MER/BCG administration in cancer patients.
"
04/01/1986 - "
This was in contrast to when MER-BCG was administered 3 and 5 weeks after DMBA; in this case the development of mammary tumors was noticeably enhanced regardless of the fat intake of the host.
"
06/01/1982 - "
Prior to the MER/BCG randomization, patients received six courses of induction and two years of maintenance chemotherapy so that a group with a presumptively low tumor burden could be established.
"
01/01/1978 - "
The predicted value of MER-BCG (Bacillus Calmette-Guerin) for the immunotherapy of solid tumors was borne out by these results suggesting that present ongoing clinical trials of MER as adjuvant therapy for large bowel cancer should prove to be successful if properly controlled.
"
12/01/1977 - "
Nine patients with advanced cancer who were receiving the methanol extraction residue of BCG (MER-BCG) intradermally or intratumorally underwent biopsies from the injected sites or from locally enlarged lymph nodes.
"
2.
Carcinogenesis
04/01/1986 - "
The magnitude of inhibition or increase by MER-BCG was similar in animals fed either fat level, although a high fat diet consistently stimulated mammary tumorigenesis in the 2 experiments.
"
04/01/1986 - "
When MER-BCG was administered 2 and 3 weeks before DMBA, mammary tumorigenesis was suppressed in the 2 dietary groups with different levels of fat intake.
"
04/01/1986 - "
The present study was designed to study the effect of dietary fat intake on the modulation of dimethylbenz[a]anthracene (DMBA)-induced mammary carcinogenesis in rats injected with the methanol extract residue of Bacillus Calmette-Guerin (MER-BCG).
"
3.
Small Cell Lung Carcinoma (Small Cell Lung Cancer)
01/01/1983 - "
Oral administration of the methanol extraction residue of BCG (MER/BCG): a phase I study in non-oat cell lung cancer patients.
"
4.
Sarcoma (Soft Tissue Sarcoma)
01/01/1978 - "
A preliminary study of cyclophosphamide (NSC-26271), adriamycin (NSC-123127), imidazole carboxamide (NSC-45388), and actinomycin D (NSC-3053) with or without MER-BCG in patients with advanced sarcomas.
"
5.
Melanoma (Melanoma, Malignant)
01/01/1979 - "
A pronounced vitiliginous reaction developed at the sites of MER/BCG injections given as an adjuvant immunotherapy to a patient with malignant melanoma.
"
11/01/1982 - "
Miliary pulmonary granulomas induced by the methanol extraction residue of BCG (MER/BCG) in patients with melanoma.
"
Related Drugs and Biologics
1.
Methanol (Carbinol)
2.
Doxorubicin (Adriamycin)
3.
Cyclophosphamide (Cytoxan)
4.
Dietary Fats (Dietary Fat)
5.
Dactinomycin (Actinomycin)
6.
anthracene
7.
imidazole
8.
Vincristine (Oncovin)
9.
Vaccines
10.
Tuberculin (PPD)
Related Therapies and Procedures
1.
Immunotherapy
2.
Therapeutics
3.
Oral Administration
4.
Injections
5.
Maintenance Chemotherapy